Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats

• Autori principali: Wenchao Zhang (Autore), Jianwei Liu (Autore), Yang Fu (Autore), Huifang Ji (Autore), Zheyan Fang (Autore), Wanming Zhou (Autore), Huimin Fan (Autore), Yingxuan Zhang (Autore), Yan Liao (Autore), Ting Yang (Autore), Xiaolin Wang (Autore), Wanwan Yuan (Autore), Xiaoshu Chen (Autore), Yi-fei Dong (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Previous studies have confirmed the clinical efficacy of sacubitril/valsartan (Sac/Val) for the treatment of heart failure with reduced ejection fraction (HFrEF). However, the role of Sac/Val in heart failure with preserved ejection fraction (HFpEF) remains unclear. Sac/Val is a combination therapeu...